Select Bibliography

Filter by any of these (after searching):

Sarkaria, Jann N.

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 8 items

Validating RNAseq-Signatures of Vorinostat (VOR) Sensitivity and Resistance in Patients with Newly Diagnosed Glioblastoma (GBM) Treated with VOR, Temozolomide and Radiation Therapy From Alliance N0874/ABTC-0902.

Anderson, S. Keith , Miller, C. Ryan , Sarkaria, Jann N. ... - ASCO - J Clin Oncol - 2016

Abstract - Secondary - Primary - Neuro-Onc - N0874 , ABTC-0902

Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177

Brown, Paul D. , Krishnan, Sunil , Sarkaria, Jann N. , Wu, Wenting ... - - J Clin Oncol - 2008

Manuscript - Primary - Primary - Neuro-Onc - N0177

Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North Central Cancer Treatment Group study N0272 (Alliance/NCCTG)

Jaeckle, Kurt A. , Anderson, S K. , Twohy, Erin L. , Dixon, Jesse G. ... - - J Neurooncol - 2019

Manuscript - Primary - Primary - Neuro-Onc - N0272

A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K

Ma, Daniel J. , Galanis, Evanthia , Anderson, S. Keith ... - - Neuro-oncology - 2015

Manuscript - Primary - Long-Term-Followup - Neuro-Onc - N057K

Randomized Phase II/III trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma (GBM) with MGMT promoter hypermethylation

Sarkaria, Jann N. , Ballman, Karla V. , Kizilbash, Sani H. ... - ASCO - J Clin Oncol - 2022

Abstract - Primary - Primary - Neuro-Onc - A071102

Combination of temsirolimus (CCI-779) with chemo-radiation in newly diagnosed GBM (NCCTG trial N027D) is associated with increased infectious risks1

Sarkaria, Jann N. , Galanis, Eva , Wu, Wenting , Dietz, Allan B. ... - - Clin Cancer Res - 2010

Manuscript - Primary - Primary - Neuro-Onc - N027D

NCCTG Phase I Trial N057K of Everolimus (RAD001) and Temozolomide in Combination with Radiation Therapy in Newly Diagnosed Glioblastoma Multiforme Patients1

Sarkaria, Jann N. , Galanis, Evanthia , Wu, Wenting ... - - Int J Radiat Oncol Biol Phys - 2011

Manuscript - Primary - Primary - Neuro-Onc - N057K

Phase I/II Trial of Temsirolimus and Sorafenib in Treatment of Patients with Recurrent Glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572

Schiff, David , Jaeckle, Kurt A , Anderson, S. Keith ... - - Cancer - 2018

Manuscript - Primary - Primary - Neuro-Onc - N0572